Keywords: Forest Labs, Gedeon Richter, Cariprazine, Ph III, acute mania
More strong data on Forest and Richter antipsychotic cariprazine
Article | 09 February 2012
US drugmaker Forest Laboratories (NYSE: FRX) has announced positive preliminary top-line results from a Phase III clinical trial of cariprazine ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
